apd791
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00529646)
Timeline
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorINVERSE AGONIST
HTR2A inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1- Mol. weight
- 436.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1084617 ↗
- ChEMBLCHEMBL2105696 ↗
Also known as
- apd791
- apd791
- apd791
- apd-791
- apd-791
- temanogrel
- temanogrel
- temanogrel hcl
- temanogrel hcl
- temanogrel hydrochloride
- temanogrel hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04915950 | Phase 2 | Aug 31, 2021 | Arena Pharmaceuticals |
| NCT04848220 | Phase 2 | Jun 8, 2021 | Arena Pharmaceuticals |
| NCT02419820 | Phase 1 | Mar 1, 2015 | IlDong Pharmaceutical Co Ltd, University of Ulsan |
| NCT02034292 | Phase 1 | Jan 1, 2014 | IlDong Pharmaceutical Co Ltd, University of Ulsan |
| NCT00619931 | Phase 1 | Jan 31, 2008 | Arena Pharmaceuticals, MDS Pharma |
| NCT00529646 | Phase 1 | Jul 1, 2007 | Arena Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 4 | 4 | 2 | 2007 |
| IlDong Pharmaceutical Co Ltd | For profit | 2 | 2 | 1 | 2014 |
| University of Ulsan | Academic/Hospital | 2 | 0 | 1 | 2014 |
| MDS Pharma | For profit | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1